RxDoctor Payments Data

Connie Dimarco, MD

Urogynecology and Reconstructive Pelvic Surgery · Springfield, ORNPI 1891712477

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,798 of the $2,639 with a category attached, or 68.1%. Intuitive Surgical accounts for 86.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,301 and has fallen 97.5% since, to $57 in 2025.

$2,639in general payments, 2019–2025

Across 21 payments — averaging $125.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Astellas Pharma US Inc$230
  • AstraZeneca$31
  • AbbVie$26
  • Johnson & Johnson$22
  • Novartis$19
  • plus $29 from 2 others

What the payments were for

  • Travel & lodging$1,79868%
  • Food & beverage$60223%
  • Education$2309%
  • Gifts$90%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,927
Medicare patients
309
Services billed
2,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron92$85,232
GemtesaVibegron73$67,144
Estradiol269$15,898
Mirabegron ErMirabegron12$8,897
PremarinEstrogens, Conjugated15$6,418
Methenamine Hippurate59$6,110
Trospium Chloride ErTrospium Chloride21$2,018
Clobetasol Propionate67$1,598
Solifenacin Succinate47$1,175
Cephalexin27$397
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$250
Oxycodone Hcl34$97
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$90
Oxybutynin Chloride15$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$230$85,23292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →